Cargando…

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma

Encouraging response has been achieved in relapsed/refractory (R/R) B-cell lymphoma treated by chimeric antigen receptor T (CAR-T) cells. The efficacy and safety of CAR-T cells in central nervous system lymphoma (CNSL) are still elusive. Here, we retrospectively analyzed 15 patients with R/R seconda...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Huanxin, Yan, Zhiling, Wang, Ying, Qi, Yuekun, Hu, Yongxian, Li, Ping, Cao, Jiang, Zhang, Meng, Xiao, Xia, Shi, Ming, Xia, Jieyun, Ma, Sha, Qiao, Jianlin, Li, Hujun, Pan, Bin, Qi, Kunming, Cheng, Hai, Sun, Haiying, Zhu, Feng, Sang, Wei, Li, Depeng, Li, Zhenyu, Zheng, Junnian, Zhao, Mingfeng, Liang, Aibin, Huang, He, Xu, Kailin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437350/ https://www.ncbi.nlm.nih.gov/pubmed/36059496 http://dx.doi.org/10.3389/fimmu.2022.965224

Ejemplares similares

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
por: Xia, Jieyun, et al.
Publicado: (2023)

An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study
por: Qi, Kunming, et al.
Publicado: (2021)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Macrophages ameliorate bone marrow inflammatory injury and promote hematopoiesis in mice following hematopoietic stem cell transplantation
por: Qiao, Jianlin, et al.
Publicado: (2018)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
por: Xia, Jieyun, et al.
Publicado: (2023)

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
por: Chen, Wei, et al.
Publicado: (2021)

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
por: Liu, Yang, et al.
Publicado: (2023)

Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023)

An absence of platelet activation following thalidomide treatment in vitro or in vivo
por: Qiao, Jianlin, et al.
Publicado: (2017)

Advantages of digital PCR in the detection of low abundance BCR-ABL1 gene in patients with chronic myeloid leukemia
por: Yan, Zhiling, et al.
Publicado: (2019)

Splenic Diffuse Red Pulp Small B-Cell Lymphoma with Gastrointestinal Hemorrhage: A Case Report and Literature Review
por: Xu, Yanqiu, et al.
Publicado: (2020)

Platycodin D inhibits platelet function and thrombus formation through inducing internalization of platelet glycoprotein receptors
por: Luo, Qi, et al.
Publicado: (2018)

Busulfan and cyclosphamide induce liver inflammation through NLRP3 activation in mice after hematopoietic stem cell transplantation
por: Qiao, Jianlin, et al.
Publicado: (2015)

NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis
por: Qiao, Jianlin, et al.
Publicado: (2018)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
por: Zhang, Qiqi, et al.
Publicado: (2022)

p47phox deficiency impairs platelet function and protects mice against arterial and venous thrombosis
por: Wang, Xiamin, et al.
Publicado: (2020)

Sjögren's Syndrome Complicated by Myeloid/Natural Killer Cell Precursor Acute Leukemia: Case Report and Review of the Literature
por: Feng, Hao, et al.
Publicado: (2016)

Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy
por: Xia, Wenjiao, et al.
Publicado: (2023)

PEDF promotes the repair of bone marrow endothelial cell injury and accelerates hematopoietic reconstruction after bone marrow transplantation
por: Ju, Wen, et al.
Publicado: (2020)

Validation of Housekeeping Genes as Reference for Reverse-Transcription-qPCR Analysis in Busulfan-Injured Microvascular Endothelial Cells
por: Ju, Wen, et al.
Publicado: (2018)

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL
por: He, Xiaoyuan, et al.
Publicado: (2019)

Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma
por: Zhang, Chen, et al.
Publicado: (2021)

The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
por: Sun, Xiaoyang, et al.
Publicado: (2019)

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

TIRC7 inhibits Th1 cells by upregulating the expression of CTLA-4 and STAT3 in mice with acute graft-versus-host disease
por: Zhu, Feng, et al.
Publicado: (2020)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells
por: Yao, Ruosi, et al.
Publicado: (2018)

iNKT: A new avenue for CAR-based cancer immunotherapy
por: Liu, Yilin, et al.
Publicado: (2022)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
por: Wang, Yiyun, et al.
Publicado: (2021)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
por: Lei, Wen, et al.
Publicado: (2021)

Prognostic Analysis of Patients with Primary Extranodal Lymphoma: A Retrospective Study
por: Shen, Hanying, et al.
Publicado: (2021)

Matrine Impairs Platelet Function and Thrombosis and Inhibits ROS Production
por: Zhang, Sixuan, et al.
Publicado: (2021)

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
por: Zhang, Qing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i2nv1h4oa9gb4u3ackumidqp90